121 related articles for article (PubMed ID: 20811662)
1. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
Furukawa K; Iida T; Shiba H; Fujiwara Y; Uwagawa T; Shimada Y; Misawa T; Ohashi T; Yanaga K
Oncol Rep; 2010 Oct; 24(4):843-50. PubMed ID: 20811662
[TBL] [Abstract][Full Text] [Related]
2. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
Fujiwara Y; Furukawa K; Haruki K; Shimada Y; Iida T; Shiba H; Uwagawa T; Ohashi T; Yanaga K
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):731-9. PubMed ID: 21484229
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.
Gocho T; Uwagawa T; Furukawa K; Haruki K; Fujiwara Y; Iwase R; Misawa T; Ohashi T; Yanaga K
Cancer Lett; 2013 Jun; 333(1):89-95. PubMed ID: 23348695
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.
Furukawa K; Ohashi T; Haruki K; Fujiwara Y; Iida T; Shiba H; Uwagawa T; Kobayashi H; Yanaga K
Cancer Lett; 2011 Jul; 306(1):92-8. PubMed ID: 21482023
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
Shirai Y; Shiba H; Iwase R; Haruki K; Fujiwara Y; Furukawa K; Uwagawa T; Ohashi T; Yanaga K
Cancer Lett; 2016 Jan; 370(2):177-84. PubMed ID: 26546875
[TBL] [Abstract][Full Text] [Related]
7. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Uwagawa T; Chiao PJ; Gocho T; Hirohara S; Misawa T; Yanaga K
Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice.
Haruki K; Shiba H; Fujiwara Y; Furukawa K; Iwase R; Uwagawa T; Misawa T; Ohashi T; Yanaga K
Surgery; 2013 Sep; 154(3):468-78. PubMed ID: 23972653
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
Fujiwara Y; Shiba H; Iwase R; Haruki K; Furukawa K; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Am Coll Surg; 2013 Feb; 216(2):320-32.e3. PubMed ID: 23219147
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.
Haruki K; Shiba H; Fujiwara Y; Furukawa K; Iwase R; Uwagawa T; Misawa T; Ohashi T; Yanaga K
Dig Dis Sci; 2013 Jan; 58(1):123-31. PubMed ID: 22806547
[TBL] [Abstract][Full Text] [Related]
13. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer.
Fujiwara Y; Furukawa K; Shimada Y; Iida T; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
Pancreas; 2011 May; 40(4):600-7. PubMed ID: 21343836
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.
Uwagawa T; Li Z; Chang Z; Xia Q; Peng B; Sclabas GM; Ishiyama S; Hung MC; Evans DB; Abbruzzese JL; Chiao PJ
Cancer; 2007 May; 109(10):2142-53. PubMed ID: 17410536
[TBL] [Abstract][Full Text] [Related]
15. Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.
Takada N; Sugano H; Shirai Y; Saito N; Hamura R; Taniai T; Uwagawa T; Yanaga K; Ikegami T; Ohashi T; Eto K
PLoS One; 2021; 16(9):e0257019. PubMed ID: 34473771
[TBL] [Abstract][Full Text] [Related]
16. Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages.
Noguchi S; Nakatsuka M; Konishi H; Kamada Y; Chekir C; Kudo T
Int Immunopharmacol; 2003 Sep; 3(9):1335-44. PubMed ID: 12890431
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
18. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
Brandi G; Tavolari S; Guarnieri T; Di Marco M; Paterini P; Macchini M; Di Girolamo S; Papi A; De Rosa F; Biasco G
Pancreas; 2014 Jan; 43(1):53-63. PubMed ID: 24201777
[TBL] [Abstract][Full Text] [Related]
19. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Manu KA; Shanmugam MK; Ramachandran L; Li F; Fong CW; Kumar AP; Tan P; Sethi G
Clin Cancer Res; 2012 Apr; 18(8):2220-9. PubMed ID: 22351692
[TBL] [Abstract][Full Text] [Related]
20. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
